Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 125,059,768
  • Shares Outstanding, K 2,443,528
  • Annual Sales, $ 17,099 M
  • Annual Income, $ 5,906 M
  • 60-Month Beta 0.58
  • Price/Sales 7.07
  • Price/Cash Flow 18.64
  • Price/Book 17.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.60
  • Number of Estimates 2
  • High Estimate 0.60
  • Low Estimate 0.59
  • Prior Year 0.68
  • Growth Rate Est. (year over year) -11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.85 +8.75%
on 05/29/19
52.53 -3.01%
on 06/12/19
+2.36 (+4.86%)
since 05/24/19
3-Month
46.47 +9.64%
on 05/16/19
52.53 -3.01%
on 06/12/19
-0.99 (-1.91%)
since 03/26/19
52-Week
41.23 +23.58%
on 10/11/18
52.83 -3.56%
on 03/20/19
+4.87 (+10.57%)
since 06/26/18

Most Recent Stories

More News
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.

AGEN : 3.04 (+0.33%)
NVO : 50.89 (-0.57%)
GILD : 67.17 (-1.91%)
GSK : 40.26 (-0.91%)
Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

NVO : 50.89 (-0.57%)
MRK : 83.38 (-2.18%)
NVS : 91.39 (-1.06%)
ABBV : 67.40 (+2.59%)
Esperoct(R) (turoctocog alfa pegol, N8-GP) approved in the EU

Bagsvaerd, Denmark, 20 June 2019 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Esperoct(R) for the treatment of adolescents (greater-than or equal...

NVO : 50.89 (-0.57%)
Alberta research competition winners leading the fight on diabetes and obesity with the NOVAD fund

The University Hospital Foundation (UHF), Government of Alberta, and Novo Nordisk Canada Inc. are proud to announce the winners of the 2019 Novo Nordisk Alberta Diabetes (NOVAD) Fund Competition. NOVAD...

NVO : 50.89 (-0.57%)
BMY or NVO: Which Is the Better Value Stock Right Now?

BMY vs. NVO: Which Stock Is the Better Value Option?

NVO : 50.89 (-0.57%)
BMY : 45.37 (-0.87%)
Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum

Gilead (GILD) up 6.9% in the year so far on strong performance of HIV franchise and pipeline development efforts.

NVO : 50.89 (-0.57%)
GILD : 67.17 (-1.91%)
GLPG : 126.08 (-0.16%)
GSK : 40.26 (-0.91%)
Novo Nordisk to present data on oral semaglutide at the 79th Annual American Diabetes Association Scientific Sessions

Novo Nordisk today announced that new data from its diabetes portfolio will be presented at the upcoming 79th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California...

NVO : 50.89 (-0.57%)
Evotec SE Reports First Quarter 2019 Results And Provides Corporate Update

NVO : 50.89 (-0.57%)
NVS : 91.39 (-1.06%)
CELGZ : 0.71 (+1.43%)
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug

Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.

AZN : 40.85 (-1.33%)
NVO : 50.89 (-0.57%)
MRK : 83.38 (-2.18%)
AGN : 164.67 (+1.38%)
NVS : 91.39 (-1.06%)
RHHBY : 35.0380 (-0.43%)
PFE : 43.00 (-1.74%)
NNIT A/S: 7/2019 NNIT announces preliminary financial results for the first three months of 2019 and adjusts the company's financial outlook

Preliminary revenue growth in Q1 2019 is 6.5% in constant currencies (7.4% in reported currencies) compared to the same period last year. This is in line with expectations, and guidance for revenue growth...

NVO : 50.89 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 51.75
1st Resistance Point 51.46
Last Price 50.89
1st Support Level 51.00
2nd Support Level 50.83

See More

52-Week High 52.83
Last Price 50.89
Fibonacci 61.8% 48.40
Fibonacci 50% 47.03
Fibonacci 38.2% 45.66
52-Week Low 41.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar